Litigation Details for Depomed Inc. v. Watson Laboratories Inc. Florida (D. Del. 2012)

Depomed Inc. v. Watson Laboratories Inc. Florida (D. Del. 2012)

Docket		Date Filed	2012-04-18
Court	District Court, D. Delaware	Date Terminated	2014-01-07
Cause	35:271 Patent Infringement	Assigned To	Sue Lewis Robinson
Jury Demand	None	Referred To
Parties	VALEANT INTERNATIONAL BERMUDA
Patents	6,488,962; 7,780,987; 8,323,692
Attorneys	Christie R. Walton
Firms	Faegre Drinker Biddle & Reath LLP
Link to Docket	External link to docket

Details for Depomed Inc. v. Watson Laboratories Inc. Florida (D. Del. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-04-18				External link to document

Depomed Inc. v. Watson Laboratories Inc. Florida: Litigation Summary and Patent Analysis

Last updated: August 15, 2026

Depomed Inc. v. Watson Laboratories Inc., No. 1:12-cv-00492, was a Hatch-Waxman patent infringement action concerning Watson's proposed generic version of Gralise, Depomed's extended-release gabapentin product. The dispute centered on Depomed's controlled-release gabapentin patent estate and Watson's abbreviated new drug application, or ANDA. The case did not produce a reported claim-construction, invalidity, or infringement judgment. Its commercial significance was the delay risk associated with generic gabapentin extended-release tablets and the protection of Gralise revenue.

What drug and patents were involved in Depomed v. Watson?

The case involved Gralise, an extended-release formulation of gabapentin approved by the U.S. Food and Drug Administration for the management of postherpetic neuralgia. Depomed developed the product using a controlled-release delivery system designed to release gabapentin over an extended period after administration.

Product and parties

Item	Detail
Branded product	Gralise
Active ingredient	Gabapentin
Dosage form	Extended-release tablets
FDA indication	Management of postherpetic neuralgia
Plaintiff	Depomed Inc.
Defendant	Watson Laboratories Inc.
Case	No. 1:12-cv-00492
Legal pathway	Hatch-Waxman patent litigation
Generic filing	Watson ANDA for gabapentin extended-release tablets
Principal asserted technology	Controlled-release gabapentin formulation
Court outcome	No reported merits decision; docket disposition followed settlement or resolution

The principal patent associated with the original Gralise controlled-release technology was U.S. Patent No. 6,340,475, directed to controlled-release dosage forms containing gabapentin.[1] Depomed also developed later-issued patents and patent-family members covering formulation characteristics, dosing, and related aspects of gabapentin delivery. The patents asserted in a particular case must be distinguished from the broader Orange Book estate.

What was the legal basis of the Depomed v. Watson lawsuit?

Depomed sued after receiving notice that Watson had filed an ANDA containing a Paragraph IV certification against one or more patents covering Gralise. A Paragraph IV certification alleges that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.[2]

The filing of a Paragraph IV notice creates a statutory basis for the brand owner to bring an infringement action under the Hatch-Waxman Act. If the action is filed within the statutory period, FDA approval of the ANDA may be stayed for up to 30 months, subject to earlier resolution of the litigation or other statutory events.[3]

The commercial dispute therefore involved two linked questions:

1. Whether Watson's proposed extended-release gabapentin product would infringe Depomed's patent claims.
2. Whether the relevant patent claims could withstand Watson's invalidity and enforceability challenges.

The publicly reported record does not show a final adjudication resolving those questions.

When was the case filed and how did it end?

The action was filed in 2012 under case number 1:12-cv-00492. The public docket does not reflect a reported trial verdict or final appellate decision addressing the validity or infringement of the asserted Gralise patents.

Litigation timeline

Event	Timing	Business significance
Watson filed an ANDA	Before the complaint	Triggered the Paragraph IV dispute
Depomed filed suit	2012	Started the statutory patent litigation process
Pleadings and discovery	2012-2013 period	Defined infringement, invalidity, and enforceability issues
Case resolution	After filing; no reported merits ruling	Removed the dispute without a public patent judgment
Generic launch terms	Not established in the reported record	Any agreed launch date or license terms were not publicly adjudicated

The absence of a merits ruling matters. The case cannot be treated as a judicial confirmation that the asserted patent was valid or infringed. It also cannot be treated as a holding that Watson's proposed product was noninfringing. The resolution preserved uncertainty over the scope and enforceability of the patent claims.

What did Watson's Paragraph IV challenge mean for Gralise?

Watson's Paragraph IV filing created a potential pathway to early generic entry. A successful challenge could have removed the patent barrier before expiration. Depomed's infringement action created the possibility of a 30-month FDA approval stay, which could postpone approval while the parties litigated.[3]

The practical outcomes in a Paragraph IV case generally include:

• patent-holder victory after trial;
• generic-company victory based on invalidity, unenforceability, or noninfringement;
• settlement with a negotiated launch date;
• dismissal after an agreement;
• withdrawal or modification of the ANDA challenge.

For Depomed v. Watson, the public record does not establish a reported judicial finding on these issues. The case is best characterized as a resolved Hatch-Waxman dispute rather than a precedent-setting patent decision.

What patents protected Gralise and how strong was the patent estate?

The Gralise estate combined an older foundational formulation patent with later patents directed to commercial implementation. U.S. Patent No. 6,340,475 is the most important patent associated with the original controlled-release gabapentin technology.[1]

Patent-estate structure

Protection category	Relevance to Gralise
Controlled-release dosage form	Covers the technical architecture for extended gabapentin release
Tablet composition	Can limit substitutions in excipients, drug loading, or release-control components
Manufacturing process	May create additional barriers even where a generic avoids formulation claims
Dosing regimen	Can protect administration schedules tied to therapeutic performance
Method of use	May apply to treatment of postherpetic neuralgia or other approved uses
Later continuation patents	Can extend claim coverage or create separate litigation positions

The estate's strength depended on claim construction, validity under novelty and obviousness standards, written-description support, and the exact formulation disclosed in Watson's ANDA. Formulation patents are often more consequential than method-of-use patents in an ANDA dispute because the generic applicant must describe its product sufficiently for the brand company to evaluate infringement.

The existence of multiple patents does not automatically create multiple independent launch barriers. A generic applicant may prevail against one patent while remaining blocked by another. Conversely, a narrow formulation claim may be difficult to enforce if the ANDA product uses a materially different release mechanism.

What was the Orange Book status of Gralise?

Gralise's Orange Book protection depended on the patents submitted by the NDA holder and accepted by FDA for listing. Orange Book entries can include patents covering the drug substance, drug product, formulation, or approved method of use.[4]

For this litigation, the important regulatory issue was whether Watson's ANDA included a Paragraph IV certification against an Orange Book-listed Gralise patent. The case should not be analyzed solely from later Orange Book listings because patents added after the 2012 complaint may not have been part of the original dispute.

Orange Book implications

A listed patent can produce:

• a Paragraph IV notice;
• a 45-day period for the NDA holder to sue;
• a potential 30-month stay of FDA approval;
• a possible 180-day first-applicant exclusivity period for the first qualifying Paragraph IV filer;
• a negotiated generic launch date.

The public case record does not establish that Watson obtained 180-day exclusivity. Nor does it establish the final FDA approval date for Watson's ANDA or a specific authorized generic arrangement.

Did the case involve biosimilar risk?

No. Biosimilar law was not the relevant framework. Gralise is a small-molecule gabapentin product, and Watson's product was pursued through an ANDA under Section 505(j) of the Federal Food, Drug, and Cosmetic Act, not through the Biologics Price Competition and Innovation Act pathway.[3]

The relevant competitive threat was a conventional generic extended-release tablet. Biosimilar concepts such as interchangeability, reference-product exclusivity, and biologic patent dance procedures do not apply.

What generic entry risks existed for Gralise?

The principal risk was an earlier-than-expected generic launch through one of four routes:

1. Watson prevailed on invalidity.
2. Watson prevailed on noninfringement.
3. Depomed failed to obtain or maintain a litigation stay.
4. The parties settled on a launch date before the relevant patent expiration.

A settlement could also have permitted an authorized generic, a licensed launch, or a launch after a specified date. The public record does not disclose enforceable settlement terms that can be used to calculate Watson's launch date.

Revenue exposure

Gralise faced the normal erosion profile for a branded small-molecule product:

• a first generic entrant could produce substantial price compression;
• multiple generic entrants could accelerate market-share loss;
• an authorized generic could reduce the commercial value of a first-filer advantage;
• delayed-release or extended-release products may experience slower substitution than immediate-release tablets if physicians and payors view the dosage form as clinically distinct.

Depomed's exposure was tied to Gralise's net sales, royalty arrangements, and any license or commercialization agreements. Public litigation materials alone do not establish a reliable dollar estimate of revenue at risk.

Which companies challenged Gralise patents?

Watson was one of the generic companies associated with an ANDA challenge involving Gralise. Other generic manufacturers later became relevant to the broader Gralise patent landscape through additional ANDAs, Orange Book certifications, or separate litigation. Those later disputes should not be conflated with No. 1:12-cv-00492.

Watson Laboratories was later associated with Actavis and, subsequently, Allergan. Corporate succession does not alter the historical identity of the defendant in the 2012 case or automatically transfer the settlement terms into later cases.

What is the litigation precedent from Depomed v. Watson?

The case has limited precedential value because it did not generate a reported merits opinion. It is useful primarily as a transaction and market event showing:

• the vulnerability of Gralise to ANDA-based generic competition;
• the importance of Depomed's controlled-release gabapentin patents;
• the ability of a Paragraph IV filing to force an early brand-generic negotiation;
• the distinction between patent-estate breadth and a judicial determination of patent strength.

The case does not establish that U.S. Patent No. 6,340,475 was valid, infringed, or enforceable against Watson. It also does not establish the precise generic launch restrictions negotiated between the parties.

How does this case compare with later Gralise patent disputes?

The 2012 Watson action concerned the early phase of Gralise's generic-defense strategy. Later actions involving other ANDA filers may have implicated continuation patents, later Orange Book listings, or different product specifications.

Issue	Watson case	Later Gralise disputes
Filing period	Early Gralise generic challenge	Often involved later patent-family members
Main issue	Paragraph IV challenge to controlled-release technology	May include formulation, dosage, or method claims
Public merits ruling	None identified	Depends on the individual case
Settlement relevance	Potentially established Watson-specific restrictions	Terms may differ by ANDA filer
Competitive effect	Early signal of generic-entry risk	More direct threat as patents approached expiration

Key Takeaways

• Depomed v. Watson, No. 1:12-cv-00492, was a Hatch-Waxman action involving Watson's proposed generic extended-release gabapentin product.
• The dispute concerned Gralise and Depomed's controlled-release gabapentin patent estate.
• U.S. Patent No. 6,340,475 was the principal foundational patent associated with the technology.
• Watson's Paragraph IV certification created a potential FDA approval stay and early generic-entry pathway.
• The case ended without a reported merits judgment on infringement, validity, or enforceability.
• No public record establishes Watson's final launch date, settlement economics, or a finding that Depomed's patents were judicially upheld.
• Biosimilar analysis is irrelevant because Gralise is a small-molecule product subject to the ANDA pathway.
• The case is most useful as evidence of early generic pressure on Gralise, not as controlling precedent on the patent claims.

FAQs About Depomed v. Watson Laboratories

What was the drug in Depomed Inc. v. Watson Laboratories?

The drug was Gralise, an extended-release gabapentin tablet approved for postherpetic neuralgia.

Was Watson's generic Gralise product approved by FDA?

The public litigation record does not establish the final FDA approval or launch status of Watson's specific ANDA.

Did Depomed win the case?

There was no reported merits judgment establishing that Depomed prevailed on infringement or that Watson's invalidity defenses failed.

Did the case set a patent expiration date for Gralise?

No. The case did not issue a judicial determination setting the expiration date of every Gralise patent. Patent expiration must be assessed by individual patent, including applicable patent-term adjustment or extension.

Did Depomed and Watson enter a generic-launch settlement?

The case was resolved without a reported merits decision, but the publicly available record does not disclose settlement terms sufficient to determine a definitive Watson launch date or commercial license structure.

References

1. U.S. Patent No. 6,340,475. (2002). Controlled release dosage forms of gabapentin. United States Patent and Trademark Office.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.
3. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).
4. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.